Cargando…

Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization

SIMPLE SUMMARY: Transarterial chemoembolization (TACE) is used to treat patients with intermediate stage hepatocellular carcinoma (HCC). However, models to accurately predict survival are lacking. The aim of our retrospective study was to attempt to validate the prognostic performance of the newly p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, David Sooik, Kim, Beom Kyung, Lee, Jae Seung, Lee, Hye Won, Park, Jun Yong, Kim, Do Young, Ahn, Sang Hoon, Kim, Seung Up
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750487/
https://www.ncbi.nlm.nih.gov/pubmed/35008231
http://dx.doi.org/10.3390/cancers14010067
_version_ 1784631471418376192
author Kim, David Sooik
Kim, Beom Kyung
Lee, Jae Seung
Lee, Hye Won
Park, Jun Yong
Kim, Do Young
Ahn, Sang Hoon
Kim, Seung Up
author_facet Kim, David Sooik
Kim, Beom Kyung
Lee, Jae Seung
Lee, Hye Won
Park, Jun Yong
Kim, Do Young
Ahn, Sang Hoon
Kim, Seung Up
author_sort Kim, David Sooik
collection PubMed
description SIMPLE SUMMARY: Transarterial chemoembolization (TACE) is used to treat patients with intermediate stage hepatocellular carcinoma (HCC). However, models to accurately predict survival are lacking. The aim of our retrospective study was to attempt to validate the prognostic performance of the newly proposed Pre- and Post-TACE-Predict models with Korean patients. In our study of 187 patients with HCC who underwent TACE, there was no significant difference between the Pre- and Post-TACE prediction models in HCC patients. Additionally, simple scoring prognosis prediction models performed similarly to or better than the Pre- and Post-TACE-Predict models in our study. Thus, simple scoring prognosis prediction models such as modified hepatoma arterial embolization prognostic (mHAP)-II and SNACOR may be useful in assessing the TACE treatment survival over the Pre- and Post-TACE-Predict models in patients with HCC. ABSTRACT: This study attempted to validate the prognostic performance of the proposed Pre- and Post-TACE (transarterial chemoembolization)-Predict models, in comparison with other models for prognostication. One-hundred-and-eighty-seven patients with HCC who underwent TACE were recruited. Regarding overall survival (OS), the predictive performance of the Pre-TACE-Predict model (one-year integrated area under the curve (iAUC) 0.685 (95% confidence interval (CI) 0.593–0.772)) was better than that of the Post-TACE-Predict model (iAUC 0.659 (95% CI 0.580–0.742)). However, there was no significant statistical difference between two models at any time point. For comparison between models using pre-treatment factors, the modified hepatoma arterial embolization prognostic (mHAP)-II model demonstrated significantly better predictive performance at one year (iAUC 0.767 (95% CI 0.683–0.847)) compared with Pre-TACE-Predict. For comparison between models using first TACE response, the SNACOR model was significantly more predictive at one year (iAUC 0.778 (95% CI 0.687–0.866) vs. 0.659 (95% CI 0.580–0.742), respectively) and three years (iAUC 0.707 (95% CI 0.646–0.770) vs. 0.624 (95% CI 0.564–0.688), respectively) than the Post-TACE-Predict model. mHAP-II and SNACOR may be preferred over the Pre- and Post-TACE-Predict models, respectively, considering their similar or better performance and the ease of application.
format Online
Article
Text
id pubmed-8750487
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87504872022-01-12 Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization Kim, David Sooik Kim, Beom Kyung Lee, Jae Seung Lee, Hye Won Park, Jun Yong Kim, Do Young Ahn, Sang Hoon Kim, Seung Up Cancers (Basel) Article SIMPLE SUMMARY: Transarterial chemoembolization (TACE) is used to treat patients with intermediate stage hepatocellular carcinoma (HCC). However, models to accurately predict survival are lacking. The aim of our retrospective study was to attempt to validate the prognostic performance of the newly proposed Pre- and Post-TACE-Predict models with Korean patients. In our study of 187 patients with HCC who underwent TACE, there was no significant difference between the Pre- and Post-TACE prediction models in HCC patients. Additionally, simple scoring prognosis prediction models performed similarly to or better than the Pre- and Post-TACE-Predict models in our study. Thus, simple scoring prognosis prediction models such as modified hepatoma arterial embolization prognostic (mHAP)-II and SNACOR may be useful in assessing the TACE treatment survival over the Pre- and Post-TACE-Predict models in patients with HCC. ABSTRACT: This study attempted to validate the prognostic performance of the proposed Pre- and Post-TACE (transarterial chemoembolization)-Predict models, in comparison with other models for prognostication. One-hundred-and-eighty-seven patients with HCC who underwent TACE were recruited. Regarding overall survival (OS), the predictive performance of the Pre-TACE-Predict model (one-year integrated area under the curve (iAUC) 0.685 (95% confidence interval (CI) 0.593–0.772)) was better than that of the Post-TACE-Predict model (iAUC 0.659 (95% CI 0.580–0.742)). However, there was no significant statistical difference between two models at any time point. For comparison between models using pre-treatment factors, the modified hepatoma arterial embolization prognostic (mHAP)-II model demonstrated significantly better predictive performance at one year (iAUC 0.767 (95% CI 0.683–0.847)) compared with Pre-TACE-Predict. For comparison between models using first TACE response, the SNACOR model was significantly more predictive at one year (iAUC 0.778 (95% CI 0.687–0.866) vs. 0.659 (95% CI 0.580–0.742), respectively) and three years (iAUC 0.707 (95% CI 0.646–0.770) vs. 0.624 (95% CI 0.564–0.688), respectively) than the Post-TACE-Predict model. mHAP-II and SNACOR may be preferred over the Pre- and Post-TACE-Predict models, respectively, considering their similar or better performance and the ease of application. MDPI 2021-12-23 /pmc/articles/PMC8750487/ /pubmed/35008231 http://dx.doi.org/10.3390/cancers14010067 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kim, David Sooik
Kim, Beom Kyung
Lee, Jae Seung
Lee, Hye Won
Park, Jun Yong
Kim, Do Young
Ahn, Sang Hoon
Kim, Seung Up
Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
title Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
title_full Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
title_fullStr Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
title_full_unstemmed Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
title_short Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
title_sort validation of pre-/post-tace-predict models among patients with hepatocellular carcinoma receiving transarterial chemoembolization
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750487/
https://www.ncbi.nlm.nih.gov/pubmed/35008231
http://dx.doi.org/10.3390/cancers14010067
work_keys_str_mv AT kimdavidsooik validationofpreposttacepredictmodelsamongpatientswithhepatocellularcarcinomareceivingtransarterialchemoembolization
AT kimbeomkyung validationofpreposttacepredictmodelsamongpatientswithhepatocellularcarcinomareceivingtransarterialchemoembolization
AT leejaeseung validationofpreposttacepredictmodelsamongpatientswithhepatocellularcarcinomareceivingtransarterialchemoembolization
AT leehyewon validationofpreposttacepredictmodelsamongpatientswithhepatocellularcarcinomareceivingtransarterialchemoembolization
AT parkjunyong validationofpreposttacepredictmodelsamongpatientswithhepatocellularcarcinomareceivingtransarterialchemoembolization
AT kimdoyoung validationofpreposttacepredictmodelsamongpatientswithhepatocellularcarcinomareceivingtransarterialchemoembolization
AT ahnsanghoon validationofpreposttacepredictmodelsamongpatientswithhepatocellularcarcinomareceivingtransarterialchemoembolization
AT kimseungup validationofpreposttacepredictmodelsamongpatientswithhepatocellularcarcinomareceivingtransarterialchemoembolization